Trial reportMediators of inflammation2014
Effect of low-dose, long-term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis.
Trial report in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 7 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Pooled it
- A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults.European respiratory review : an official journal of the European Respiratory Society · 2019Pooled it
- Macrolide antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2018Pooled it
- The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms.Frontiers in immunology · 2018Pooled it
- Neutrophil elastase in bronchiectasis.Respiratory research · 2017Pooled it
- Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.The Cochrane database of systematic reviews · 2015Pooled it
- Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: A systematic review and adjusted indirect treatment comparison.Chronic respiratory diseasePooled it
- Long-Term Macrolides in Chronic Respiratory Diseases: Dusk or a New Dawn? A Narrative Review.Antibiotics (Basel, Switzerland) · 2025Review
- "Pleiotropic" Effects of Antibiotics: New Modulators in Human Diseases.Antibiotics (Basel, Switzerland) · 2024Review
- Bronchiectasis in renal transplant patients: a cross-sectional study.European journal of medical research · 2024Article
- The effect of azithromycin on sputum inflammatory markers in bronchiectasis.BMC pulmonary medicine · 2023Article
- Immunomodulatory Effects of Macrolides Considering Evidence from Human and Veterinary Medicine.Microorganisms · 2022Review
- Immunomodulation by Tetracyclines in the Critically Ill: An Emerging Treatment Option?Critical care (London, England) · 2022Review
- Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells.Acta pharmacologica Sinica · 2021Article
- The immunomodulatory effects of macrolide antibiotics in respiratory disease.Pulmonary pharmacology & therapeutics · 2021Review
- Plasma pentraxin 3 is higher in early ovarian hyperstimulation syndrome than in uncomplicated in vitro fertilization cycle of high-risk women.Archives of gynecology and obstetrics · 2020Article
- Erythromycin Suppresses the Cigarette Smoke Extract-Exposed Dendritic Cell-Mediated Polarization of CD4Journal of immunology research · 2020Article
- Challenges of diagnosing and managing bronchiectasis in resource-limited settings: a case study.The Pan African medical journal · 2019Article
- Bronchiectasis in the Last Five Years: New Developments.Journal of clinical medicine · 2016Review
- Expert recommendations on the role of macrolides in chronic respiratory diseases.Lung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNoncystic fibrosis bronchiectasis (NCFB) is characterized by airway expansion and recurrent acute exacerbations. Macrolide has been shown to exhibit anti-inflammatory effects in some chronic airway diseases.
objectiveTo assess the efficacy of roxithromycin on airway inflammation and remodeling in patients with NCFB under steady state.
methodsThe study involved an open-label design in 52 eligible Chinese patients with NCFB, who were assigned to control (receiving no treatment) and roxithromycin (receiving 150 mg/day for 6 months) groups. At baseline and 6 months, the inflammatory markers such as interleukin- (IL-)8, neutrophil elastase (NE), matrix metalloproteinase- (MMP)9, hyaluronidase (HA), and type IV collagen in sputum were measured, along with the detection of dilated bronchus by throat computed tomography scan, and assessed the exacerbation.
resultsForty-three patients completed the study. The neutrophil in the sputum was decreased in roxithromycin group compared with control (P < 0.05). IL-8, NE, MMP-9, HA, and type IV collagen in sputum were also decreased in roxithromycin group compared with the control group (all P < 0.01). Airway thickness of dilated bronchus and exacerbation were reduced in roxithromycin group compared with the control (all P < 0.05).
conclusionsRoxithromycin can reduce airway inflammation and airway thickness of dilated bronchus in patients with NCFB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.